Activation, Apathy, Anergy and Apoptosis in Transplantation

移植中的激活、冷漠、无反应和细胞凋亡

基本信息

  • 批准号:
    7315388
  • 负责人:
  • 金额:
    $ 37.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1996
  • 资助国家:
    美国
  • 起止时间:
    1996-12-01 至 2011-12-31
  • 项目状态:
    已结题

项目摘要

Transplantation is the preferred mode of therapy for many forms of end-stage organ disese. Success in transplantation has been built around therapeutic approaches to control the T cell-dependent process of rejection. Current therapies control rejection but cause numerous non-immune toxicities. In the past few years the concept of controlling rejection with more immuno-selective approaches by targeting T cell costimulatory pathways has shown promise in clinical trials. While very effective in many experimental rejection models, it is widely recognized that costimulation blockade approaches targeting CD28 and/or CD40 do not uniformly control rejection responses. As these strategies progress in clinical trials the need to dissect the mechanisms by which T cells can escape blockade of these pathways becomes more pressing. Over the past several years, the Programmed Differentiation Model has emerged as a new pardigm to understand T cell responses. This model is based on evidence that after a brief period of antigenic stimulation, T cells become committed to a program of autonomous clonal expansion of several rounds of cell division and differentiation into effector cells. However, T cell programs are flexible and can be altered by the initial priming conditions and by extrinsic factors during the execution of the program. Two findings of particular relevance to transplantation are recent studies indicating 1) that the initial precursor frequency of the responding population is a powerful influence on the program and that high initial CD8+ T cell frequencies can convert helper dependent responses into helper-independent and costimulation- independent responses, and 2) that both IL-2and IFNg can play critical roles during the antigen-independent expansion/differentiation phase of the CD8+ T cell program. Experimental evidence suggest that between 0.1-10% of a naive individual's T cell repertoire is capable of reacting with alloantigens, a figure that is 2-3 logs greater than the estimated precursor frequency of virus- specific T cell responses. The central hypothesis of this proposal is that variation in the initial precursor frequencies of donor-reactive CD4 and/or CDS T cells is a critical determinant in the susceptibility or resistance to CD28/CD40 costimulation blockade induced graft acceptance.
移植是许多终末期器官疾病的首选治疗方式。成功的

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHRISTIAN P LARSEN其他文献

CHRISTIAN P LARSEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHRISTIAN P LARSEN', 18)}}的其他基金

Admin-Core-001
管理核心-001
  • 批准号:
    10609608
  • 财政年份:
    2022
  • 资助金额:
    $ 37.52万
  • 项目类别:
Transplant Tolerance in Non-Human Primates
非人类灵长类动物的移植耐受性
  • 批准号:
    10518465
  • 财政年份:
    2022
  • 资助金额:
    $ 37.52万
  • 项目类别:
Core-001
核心001
  • 批准号:
    10609609
  • 财政年份:
    2022
  • 资助金额:
    $ 37.52万
  • 项目类别:
Cellular Strategies for Tolerance Induction
耐受诱导的细胞策略
  • 批准号:
    10609610
  • 财政年份:
    2022
  • 资助金额:
    $ 37.52万
  • 项目类别:
Third Generation Costimulation Blockade-Based Tolerance Strategies
第三代基于共刺激封锁的耐受策略
  • 批准号:
    8705983
  • 财政年份:
    2014
  • 资助金额:
    $ 37.52万
  • 项目类别:
TRANSPLANT TOLERANCE IN NONHUMAN PRIMATES
非人类灵长类动物的移植耐受性
  • 批准号:
    8357393
  • 财政年份:
    2011
  • 资助金额:
    $ 37.52万
  • 项目类别:
TRANSLATIONAL STRATEGIES FOR PANCREATIC ISLET XENOTRANSPLANTATION IN NHP
NHP 胰岛异种移植的翻译策略
  • 批准号:
    8357464
  • 财政年份:
    2011
  • 资助金额:
    $ 37.52万
  • 项目类别:
OPTIMIZING IMMUNOTHERAPY FOR ALLOGENEIC ISLET TRANSPLANTATION IN NHP
优化 NHP 异体胰岛移植的免疫治疗
  • 批准号:
    8357444
  • 财政年份:
    2011
  • 资助金额:
    $ 37.52万
  • 项目类别:
TRANSLATIONAL STRATEGIES FOR PANCREATIC ISLET XENOTRANSPLANTATION IN NHP
NHP 胰岛异种移植的翻译策略
  • 批准号:
    8172418
  • 财政年份:
    2010
  • 资助金额:
    $ 37.52万
  • 项目类别:
TRANSPLANT TOLERANCE IN NONHUMAN PRIMATES
非人类灵长类动物的移植耐受性
  • 批准号:
    8172322
  • 财政年份:
    2010
  • 资助金额:
    $ 37.52万
  • 项目类别:

相似海外基金

Establishment of novel osteochondral allografting combined with growth factor- collagen-binding domain fusion technology
新型同种异体骨软骨移植联合生长因子-胶原蛋白结合域融合技术的建立
  • 批准号:
    26462277
  • 财政年份:
    2014
  • 资助金额:
    $ 37.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Translating PTH Therapy as an Adjuvant for Structural Allografting
将 PTH 疗法转化为结构性同种异体移植的佐剂
  • 批准号:
    8344380
  • 财政年份:
    2012
  • 资助金额:
    $ 37.52万
  • 项目类别:
Allografting for Lukemia
白血病同种异体移植
  • 批准号:
    8260361
  • 财政年份:
    2011
  • 资助金额:
    $ 37.52万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7878675
  • 财政年份:
    2009
  • 资助金额:
    $ 37.52万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7677758
  • 财政年份:
    2009
  • 资助金额:
    $ 37.52万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7466112
  • 财政年份:
    2008
  • 资助金额:
    $ 37.52万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8010394
  • 财政年份:
    2008
  • 资助金额:
    $ 37.52万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8208131
  • 财政年份:
    2008
  • 资助金额:
    $ 37.52万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7575273
  • 财政年份:
    2008
  • 资助金额:
    $ 37.52万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7765518
  • 财政年份:
    2008
  • 资助金额:
    $ 37.52万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了